Banque Cantonale Vaudoise’s Akero Therapeutics AKRO Stock Holding History

Banque Cantonale Vaudoise’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,000	Closed	-$23K	–	752
2024 Q2	$23K	Hold	1,000	–	–	﹤0.01%	867
2024 Q1	$25K	Hold	1,000	–	–	﹤0.01%	854
2023 Q4	$23K	Hold	1,000	–	–	﹤0.01%	883
2023 Q3	$51K	Hold	1,000	–	–	﹤0.01%	966
2023 Q2	$47K	Hold	1,000	–	–	﹤0.01%	971
2023 Q1	$38K	Hold	1,000	–	–	﹤0.01%	997
2022 Q4	$55K	Hold	1,000	–	–	﹤0.01%	942
2022 Q3	$34K	Hold	1,000	–	–	﹤0.01%	1046
2022 Q2	$9K	Hold	1,000	–	–	﹤0.01%	1187
2022 Q1	$14K	Hold	1,000	–	–	﹤0.01%	1185
2021 Q4	$21K	Hold	1,000	–	–	﹤0.01%	1181
2021 Q3	$22K	Hold	1,000	–	–	﹤0.01%	1151
2021 Q2	$25K	Hold	1,000	–	–	﹤0.01%	1140
2021 Q1	$29K	Buy	+1,000	New	+$30.3K	﹤0.01%	1042

Other funds holding AKRO

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Banque Cantonale Vaudoise's AKRO Position: Q3 2024 in Review

Banque Cantonale Vaudoise sold out of Akero Therapeutics (AKRO) in Q3 2024, closing a stake of 1,000 shares — an estimated $23K sold.

Banque Cantonale Vaudoise first reported a position in AKRO in Q1 2021 and held it in 14 quarters. The position peaked at $55K in Q4 2022. 168 funds tracked by Wall St. Rank hold AKRO as of Q3 2024.

Banque Cantonale Vaudoise reported no remaining Akero Therapeutics position as of Q3 2024 after selling out during the quarter.
Banque Cantonale Vaudoise sold 1,000 Akero Therapeutics shares in Q3 2024, an estimated $23K.
Banque Cantonale Vaudoise first reported a position in Akero Therapeutics in Q1 2021 and held it in 14 quarters.
Banque Cantonale Vaudoise's Akero Therapeutics position peaked at $55K in Q4 2022.
168 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2024.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2024, filed 8 Nov 2024.